Acrivon Therapeutics, Inc. ACRV 深 滬
等待開盤 12-15 09:30:00 美东时间
2.53
-0.080
-3.07%
華盛通- 最 高2.72
- 今 開2.63
- 成交量 36.49万股
- 最 低 2.5135
- 昨 收 2.61
- 總市值 7983.44万
- 52周最高 8.00
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 1.05
- 委 比 -27.27%
- 總股本 3155.51万
- 歷史最高 25.47
- 量 比 0.72
- 振 幅 7.91%
- 歷史最低 1.05
- 每 手 1
- 風險率 1.93%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 安捷伦科技、Keysight、先科电子获多家大行上调目标价；摩根大通下调亿航智能评级至"中性"，目标价下调至13美元
今日重点评级关注：HC Wainwright & Co.：维持BiomX"买入"评级，目标价从15美元升至26美元；Clear Street：维持Diversified Energy"买入"评级，目标价从23美元升至25美元
11-26 10:07
HC Wainwright & Co. Reiterates Buy on Acrivon Therapeutics, Maintains $19 Price Target
HC Wainwright & Co. analyst Emily Bodnar reiterates Acrivon Therapeutics (NASDAQ:ACRV) with a Buy and maintains $19 price target.
11-25 19:45
Acrivon Therapeutics Q3 EPS $(0.47) Beats $(0.61) Estimate
Acrivon Therapeutics (NASDAQ:ACRV) reported quarterly losses of $(0.47) per share which beat the analyst consensus estimate of $(0.61) by 22.57 percent. This is a 20.34 percent increase over losses of $(0.59) per share
11-14 05:13
Acrivon Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights
- Advancement ofRegistrational-intent Phase 2b trialofACR-368 andPhase1 trial ofACR-2316 in endometrial cancer andsolid tumor types. - Expansion ofGenerative Phosphoproteomics AP3 platform for target-centric drug discovery. - Financial update:Cash, cash equivalents, and marketable securities of$134.4 million as ofSeptember30, 2025. - Anticipated milestones:Reporting Phase2b trial update forACR-368 andPhase1clinical data forACR-2316 in2025.
11-13 21:10
Acrivon Therapeutics To Deliver Three Presentations At The AACR-NCI-EORTC Highlighting Advances From Its Proprietary Generative Phosphoproteomics AP3 Platform For Developing Precision Medicines
AP3 Generative AI KaiSR model globally assesses drug effects on the entire intracellular protein signaling network for optimal drug design and precision medicine developmentFavorable ACR-2316 preclinical data,
10-23 04:29
Acrivon Therapeutics Highlights its Powerful Generative Phosphoproteomics AP3 Platform with Compelling Preclinical Data for ACR-2316 with Three Presentations at the Upcoming AACR-NCI-EORTC International Conference
Acrivon Therapeutics announced three presentations at the AACR-NCI-EORTC conference showcasing their AP3 Generative AI platform and drug ACR-2316. The platform assesses drug effects on intracellular protein signaling networks for optimal drug design. ACR-2316, a WEE1/PKMYT1 inhibitor, demonstrated superior preclinical activity. Initial clinical data from its Phase 1 trial is expected later this year, with clinical activity already observed during...
10-22 20:15
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Acrivon Therapeutics granted equity awards in the form of stock options to an employee under its 2023 Inducement Plan. The options, totaling 225,000 shares, vest over four years with 25% after the first anniversary and monthly installments thereafter. Acrivon, a biotech company leveraging its proprietary Generative Phosphoproteomics AP3 platform, is advancing precision medicines, including ACR-368 in a Phase 2 trial for endometrial cancer and ACR...
10-01 20:30
Why Robinhood Shares Are Trading Higher By Over 7%; Here Are 20 Stocks Moving Premarket
Shares of Robinhood Markets, Inc. (NASDAQ:HOOD) rose sharply in pre-market trad...
09-08 17:30
Acrivon Therapeutics Highlights Synergy in Updated Presentation
An update from Acrivon Therapeutics, Inc. ( ($ACRV) ) is now available. On Sept...
09-06 04:47
Analysts Offer Insights on Healthcare Companies: Acrivon Therapeutics, Inc. (ACRV) and Jazz Pharmaceuticals (JAZZ)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts jus...
08-28 17:50
